LLASHNEWSMedical aesthetics media & sourcingRequest Quote
RegulatoryInjectables

【South Korea 】South Korea Designates Three Injectable Drugs as National Essential Medicines

Source image preserved for article context.
Editor's note

This designation, sourced from the MFDS, signals tighter regulatory oversight on injectable supply chains in South Korea, posing potential sourcing and pricing risks for overseas medical aesthetics buyers of similar products.

South Korea's Ministry of Food and Drug Safety (MFDS) has designated three injectable medicines—dacarbazine, doxorubicin, and cisatracurium—as national essential medicines, expanding the list to 491 products. For overseas medical aesthetics buyers and distributors, this signals tighter regulatory oversight on injectable supply chains, potentially affecting sourcing and pricing of similar products used in aesthetic clinics.

Regulatory context

The MFDS announced the designation on Tuesday, adding dacarbazine injection (for malignant melanoma and Hodgkin lymphoma), doxorubicin injection (lyophilized powder for TACE procedures in hepatocellular carcinoma), and cisatracurium injection (a neuromuscular blocking agent for anesthesia). National essential medicines are those deemed clinically indispensable but facing supply instability, requiring government support.

Market signal

With these additions, the total number of national essential medicines in South Korea has risen from 488 to 491. The designation process is overseen by the National Essential Medicines Supply Stability Council, established within the MFDS in 2016. The council includes 10 central government agencies, including the Office for Government Policy Coordination.

Official statement

Vice Minister Kim Yong-jae, chair of the council, said: "We moved quickly to designate anticancer injectables and other medicines whose stable supply is critically needed in healthcare settings. We will continue working to ensure that cancer patients can use these medicines with confidence, free from concerns about supply shortages."

What buyers should watch

For overseas importers and distributors of injectable products, this designation may lead to tighter supply controls and potential price adjustments for similar drugs in South Korea. Aesthetic clinics using injectable anesthetics or anticancer agents should monitor regulatory changes that could affect cross-border sourcing. The MFDS's proactive stance may also influence other markets to review their essential medicines lists.

Source: Read the original report | Published: June 04, 2026